Showing results (651-660 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 24, 2009
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumorsDarren R Feldman, Stefan Turkula, Michelle S Ginsberg, et al.
Investigational New Drugs|June 24, 2009
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinomaJudith Michels, Nathalie Lassau, Marine Gross-Goupil, et al.
Investigational New Drugs|July 1, 2009
Phase II study of darinaparsin in patients with advanced hepatocellular carcinomaJennifer Wu, Charles Henderson, Lynn Feun, et al.
Investigational New Drugs|July 4, 2009
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancerIn Hae Park, Jungsil Ro, Keun Seok Lee, et al.
Investigational New Drugs|January 28, 2009
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell linesBrigette B Y Ma, Fion Sung, Qian Tao, et al.
Investigational New Drugs|October 15, 2008
Chemopreventive potential of Epoxy clerodane diterpene from Tinospora cordifolia against diethylnitrosamine-induced hepatocellular carcinomaMuniyappan Dhanasekaran, Arul-Albert Baskar, Savarimuthu Ignacimuthu, et al.
Investigational New Drugs|December 6, 2008
Inhibitory effect of tea polyphenols on hepatic preneoplastic foci in Wistar ratsSmita Srivastava, Madhulika Singh, Preeti Roy, et al.
Investigational New Drugs|January 14, 2009
Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cellsChristof Seidl, Matthias Port, Christos Apostolidis, et al.
Investigational New Drugs|January 14, 2009
Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cellKathy Ka-Wai Auyeung, Joshua Ka-Shun Ko
Investigational New Drugs|January 17, 2009
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma modelR Graeser, N Esser, H Unger, et al.
Pageof 372